Blog

The United States autoinjectors market is being reshaped by three forces at once: the shift of biologics and GLP-1 therapies into home settings, growing demand for emergency-ready devices such as epinephrine and naloxone pens, and a wave of partnerships between drug makers and device specialists. This blog reviews ten companies that are shaping the U.S. market, based on their official product pages, recent announcements and annual reports. For full market sizing, segment forecasts and competitive share, download the free sample of the United States Autoinjectors Market report.

Source: Global Data Route Analytics analysis of company websites, product pages, press releases and annual reports

Why Autoinjectors Matter in the U.S. Healthcare System

An autoinjector is a spring-loaded, pre-filled device that lets patients or caregivers deliver a fixed dose without handling a needle and syringe. In the U.S., these devices now cover life-saving emergency drugs, chronic biologics for autoimmune and blood disorders, migraine therapies and the fast-growing obesity segment. The common thread is the move from clinic-administered injections to safe, simple self-injection at home.

The companies below fall into two broad groups: drug owners who put their medicines into branded pens, and device and drug-delivery specialists who design and manufacture the platforms those drugs are filled into. Understanding how these groups work together is key to reading the market. Our analyst team can walk you through the full competitive map.

Therapy Areas Driving Demand

Mapping every product reference in our source set shows that platform devices and emergency medicine lead the landscape, while obesity, migraine and hematology are the newest growth pockets. Emergency use is anchored by epinephrine brands such as Auvi-Q and Amneal's epinephrine autoinjector, along with Kaléo's naloxone autoinjector for opioid overdose. On the chronic side, therapies like Zepbound and Aimovig show how large patient populations are moving to pen-based dosing.

Recent Developments: What Companies Are Doing

We tracked 21 recent announcements across the ten companies. Product launches and regulatory milestones are the largest category, followed closely by partnerships and licensing deals. This tells us that competition is being fought on two fronts: getting new drug-device combinations approved, and securing the device technology to deliver them.

Key Development Timeline

Source: Company press releases and news coverage linked above

Company Analysis: Key Players in the U.S. Autoinjectors Market

1. Becton, Dickinson and Company (BD)

BD is one of the largest device suppliers in this space. Its Physioject disposable autoinjector and wider self-injection systems portfolio serve drug makers who need a ready platform (see the Physioject brochure and product specifications). BD's tie-up with Ypsomed and its syringe-autoinjector combination show a clear focus on large-volume, high-viscosity biologics.

Company links: Website | About | Contact | Annual report / financials

2. AbbVie Inc

AbbVie is a major biologics owner whose self-injected therapies depend on pen design. Industrial design work on its devices is shown by Design Integrity, and a historic Eisai partnership notice relates to its injectable portfolio. Its latest move is an AI-driven drug discovery collaboration with Iambic, which may feed future injectable pipelines.

Company links: Website | About | Contact | Annual report / financials

3. Amgen Inc.

Amgen has one of the longest autoinjector track records, from SureClick to AutoTouch and the Aimovig pen for migraine prevention. It also secured device know-how through a licence agreement with Kaléo for autoinjector technology.

Company links: Website | About | Contact | Annual report / financials

4. Eli Lilly and Company

Lilly leads the obesity and diabetes pen segment. Its Zepbound KwikPen instructions for use and the Zepbound product site highlight the shift to multi-dose pens that make monthly supply easier for patients.

Company links: Website | About | Contact | Annual report / financials

5. Viatris Inc

Viatris is a key U.S. name in emergency epinephrine, with products listed in its catalogue (product 1, product 2, product 3). Recent moves include a global research deal with Idorsia, an FDA-accepted NDA for fast-acting meloxicam and the acquisition of Aculys Pharma.

Company links: Website | About | Contact | Annual report / financials

6. Kaléo, Inc.

Kaléo is the most autoinjector-focused company in our list. Beyond Auvi-Q and its naloxone device, it offers the Aerio platform to partners. It has licensed its technology to Amgen and made Allerject available in Canada.

Company links: Website | About | Contact | Annual report / financials

7. Amneal Pharmaceuticals, Inc.

Amneal combines branded and generic strategies. Brekiya's prescribing information marks its entry into neurology autoinjectors, while its generic tirzepatide filing targets the obesity boom. It also announced FDA approval and launch of lanreotide injection.

Company links: Website | About | Contact | Annual report / financials

8. Pfizer Inc.

Pfizer is closely tied to the EpiPen supply chain, as shown in its EpiPen supply notice and U.S. supply update. In hematology, the FDA approved Hympavzi for two additional indications, expanding its injectable reach.

Company links: Website | About | Contact | Annual report / financials

9. Halozyme, Inc.

Halozyme turned into a drug-delivery powerhouse after it acquired Antares. It offers high-volume autoinjectors (HVAI), small-volume autoinjectors (SVAI), development services and a broader device portfolio. It has also acquired Elektrofi and raised $1.05 billion through convertible notes.

Company links: Website | About | Contact | Annual report / financials

10. West Pharmaceutical Services, Inc.

West supplies components and self-injection platforms to drug makers. Recent moves include an agreement to sell certain manufacturing and supply rights, a pre-fillable syringe platform and a Dublin expansion for diabetes and obesity injectables.

Company links: Website | About | Contact | Annual report / financials

BD and Halozyme have the most public material on autoinjectors, which reflects their role as platform suppliers that market directly to pharma customers. Viatris ranks next because of its active deal flow in 2025 and 2026.

Competitive Landscape

The U.S. autoinjectors market is moderately concentrated. A small group of large drug owners controls the best-known branded pens, while a handful of device specialists supply the platforms behind many of them. The table below shows where each company sits.

Source: Global Data Route Analytics analysis of company websites, product pages, press releases and annual reports

Vendor Landscape

Behind every branded pen is a supply chain of device designers, component makers and fill-finish partners. Drug owners increasingly buy proven platforms instead of building devices from scratch, which gives platform vendors strong influence.

Source: Global Data Route Analytics analysis of company websites, product pages, press releases and annual reports

Competitive Environment

Using a Porter's Five Forces view, rivalry is the strongest force, driven by crowded obesity and epinephrine segments. Strict FDA combination-product rules keep new entrants in check.

Source: Global Data Route Analytics analyst assessment based on company websites, press releases and annual reports (indicative scoring, not market share)

Merger & Acquisition Analysis

Deal activity shows two clear goals: buying device know-how, and adding pipeline assets that can be delivered by autoinjector. Halozyme is the most acquisitive company in our set.

Source: Company press releases and news coverage (linked in table)

Strategy Framework

The framework below maps the strategies each company used in its recent announcements. Launches and partnerships are the most common tools, while capacity expansion is concentrated among device suppliers.

Source: Global Data Route Analytics analyst assessment based on company websites, press releases and annual reports (indicative scoring, not market share)

Heat Map Analysis

The heat map scores each company's presence in major autoinjector segments. Darker cells mean stronger presence. It shows clear white space: few companies cover both emergency and obesity, and platform strength sits almost entirely with device suppliers.

Biologics platforms (10) and emergency devices (9) have the highest combined scores, while obesity (5) is less crowded despite fast growth. That makes obesity pens a strong opportunity for new device partnerships. Ask our analysts about white-space opportunities.

Key Takeaways

• Obesity is the new growth engine: Lilly's pen upgrades and early generic tirzepatide filings point to strong and lasting device demand.
• Device specialists hold the keys: BD, West and Halozyme supply the platforms many brands rely on, making partnerships a core strategy.
• Emergency devices stay essential: epinephrine and naloxone autoinjectors remain a steady, policy-sensitive segment.
• High-viscosity biologics need new designs: larger-volume autoinjectors are a clear focus for BD, Ypsomed and Halozyme.

Want the numbers behind these trends? Get the free sample report, send us your questions or ask for a special discount on the full United States Autoinjectors Market study.

Disclaimer: This blog is based on publicly available company information linked in each section. Product and brand names belong to their respective owners.